Financiado en parte por Pfizer, Pfizer Australia
Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity
Chan DC, Watts GF, Barrett PH, Beilin LJ, Mori TA
Clinical chemistry · 99 citas
Etiquetas de revisión
Financiado por la industriaSolo mecanismosDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Solo mecanismos
Quién lo pagó
- Financiación
- Financiado por la industria
- Empresa
- Pfizer
- Empresa
- Pfizer Australia
- Organización sin fines de lucro
- National Heart Foundation of Australia
- Gobierno
- National Institutes of Health
- Gobierno
- Medical Research Council
- Gobierno
- National Center for Research Resources
- Gobierno
- NCRR NIH HHS
- Subvenciones
- National Center for Research Resources (RR12609)
Según 7 financiadores declarados.
Publicación
- Publicado
- 2002-06-01 · Clin Chem · vol. 48 · número 6 · págs. 877–883
- Editorial
- American Association for Clinical Chemistry
- Citado
- 150 citas · más que el 99% de estudios similares · 12.4× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 51 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Lipoproteins and Cardiovascular Health · Fatty Acid Research and Health · Adipokines, Inflammation, and Metabolic Diseases
- Palabras clave
- fish oil, high-sensitivity C-reactive protein, visceral obesity, low-grade inflammation, interleukin-6, TNF-α, statins, anti-inflammatory activity, dyslipidemia, atherosclerosis risk
- MeSH
- humans, obesity, pyrroles, hydroxymethylglutaryl coa reductases, heptanoic acids, fish oils, tumor necrosis factor-alpha, c-reactive protein, interleukin-6, anticholesteremic agents, enzyme inhibitors, immunoassay, colorimetry, cross-sectional studies, middle aged, male, biomarkers, atorvastatin
5 autores
- Dick C. Chan🇦🇺The University of Western Australia; Royal Perth Hospital
- Gerald F. Watts🇦🇺 · autor de correspondenciaThe University of Western Australia; Royal Perth Hospital
- P. Hugh R. Barrett🇦🇺The University of Western Australia; Royal Perth Hospital
- Lawrence Joseph Beilin🇦🇺The University of Western Australia; Royal Perth Hospital
- Trevor Anthony Mori🇦🇺The University of Western Australia; Royal Perth Hospital
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Chronic low-grade inflammation may contribute to the increased risk of atherosclerosis in visceral obesity. Statin and fish oil have been reported to have antiinflammatory effects. We studied whether dyslipidemic, obese individuals have increased plasma high-sensitivity C-reactive protein (hs-CRP) concentrations and whether treatment with atorvastatin and fish oil lowered plasma hs-CRP concentrations.
Methods
We compared plasma hs-CRP, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) concentrations in 48 obese individuals with the concentrations in 10 lean normolipidemic men. The obese individuals were then randomized to treatment with atorvastatin (40 mg/day), fish oil (4 g/day), atorvastatin plus fish oil, or matching placebo for 6 weeks.
Results
Compared with controls, obese individuals had increased hs-CRP [geometric mean, 2.19 mg/L (95% confidence interval, 2.15-3.15 mg/L) vs 0.49 mg/L (0.30- 0.93 mg/L); P <0.001] and IL-6 [351 pg/L (318-449 pg/L) vs 251 pg/L (211-305 pg/L); P <0.01]. Atorvastatin treatment had a significant main effect of decreasing plasma hs-CRP (-0.87 mg/L; 95% confidence interval, -0.10 to -1.60 mg/L; P <0.01) and IL-6 (-70 pg/L; 10 to -140 pg/L; P <0.01), but this was not seen with fish oil. The reductions in hs-CRP with atorvastatin were not significantly correlated to changes in plasma lipids, IL-6, insulin resistance, or cholesterogenesis. Plasma TNF-alpha concentrations in obese individuals, however, were neither statistically different from concentrations in the lean controls nor altered with atorvastatin or fish oil treatment.
Conclusions
This study shows that visceral obesity is associated with increased plasma hs-CRP and IL-6 and, hence, a low-grade chronic inflammatory state and that treatment with atorvastatin or atorvastatin with fish oil, but not fish oil alone, reverses this abnormality.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.